Penumbra INC

Penumbra, Inc. announced its second quarter 2026 financial results, showing a 14.9% increase in total revenue to $390.0 million, driven by strong performance in both thrombectomy and embolization/access product lines.

Penumbra, Inc. announced that its stockholders have approved the merger agreement with Boston Scientific Corporation at a special meeting held on May 6, 2026.

Penumbra, Inc. announced first quarter 2026 financial results, showing a 15.6% increase in revenue to $374.8 million, with global thrombectomy revenue up 12.1% and embolization and access revenue up 23.8%.

Penumbra, Inc. announced robust financial results for the fourth quarter and full year 2025, alongside the disclosure of its proposed acquisition by Boston Scientific Corporation.

Boston Scientific Corporation will acquire Penumbra, Inc. in a cash and stock transaction valued at $374 per share, expanding its cardiovascular and neurovascular portfolios.

Penumbra, Inc. announced robust third-quarter 2025 financial results, with revenue up 17.8% to $354.7 million, and increased its full-year 2025 revenue guidance.

Penumbra, Inc. announces robust revenue growth in Q2 2026, driven by strong performance in thrombectomy and embolization products, while progressing towards its acquisition by Boston Scientific.

Penumbra, Inc. reported a 15.6% increase in revenue for the first quarter of 2026, driven by strong performance in thrombectomy and embolization products, while preparing for its acquisition by Boston Scientific.

Penumbra, Inc. reported a significant increase in revenue and net income for the third quarter and first nine months of 2025, driven by strong sales of its thrombectomy and embolization and access products.

Penumbra, Inc. announced a significant return to profitability and robust revenue growth in its second quarter and first half of 2025, driven by strong U.S. sales and improved gross margins.

Penumbra Inc. announces a 16.3% increase in revenue for Q1 2025, primarily driven by strong sales of its thrombectomy products.

Penumbra Inc. reported its third quarter 2024 results, including a strategic decision to exit its Immersive Healthcare business, impacting financials with impairment charges and restructuring costs.

Penumbra, a leading thrombectomy company, announced its acquisition by Boston Scientific for approximately $14.5 billion, following a year of strong revenue and operational income growth.

Penumbra's 2024 10-K filing highlights a strategic exit from the Immersive Healthcare business alongside a 12.9% revenue increase driven by its thrombectomy product line.

Penumbra Inc. saw a significant revenue increase in 2023, driven by strong performance in its thrombectomy product category and overall growth in international markets.

Penumbra CEO Adam Elsesser donated 77,000 shares of common stock to a charitable organization.

Penumbra, Inc. announced that its stockholders overwhelmingly approved the merger agreement with Boston Scientific Corporation at a special meeting held on May 6, 2026.

Penumbra Inc. urges stockholders to vote FOR the proposed merger with Boston Scientific Corporation, emphasizing the importance of their vote for the upcoming Special Meeting.

Boston Scientific confirms its commitment to the Penumbra acquisition during its Q1 2026 earnings call, targeting a second-half 2026 close.

Penumbra, Inc. is urging its stockholders to vote in favor of the proposed merger with Boston Scientific Corporation at the upcoming Special Meeting on May 6, 2026.

Director Harpreet Grewal sold 100 shares of Penumbra Inc stock on April 2, 2026, under a pre-arranged trading plan.

Penumbra, Inc. has announced its 2026 Annual Meeting of Stockholders and a definitive merger agreement with Boston Scientific Corporation.

Penumbra, Inc. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.

Penumbra, Inc. is holding its annual meeting on May 28, 2025, to vote on director elections, auditor ratification, executive compensation, and amendments to the company's charter regarding board declassification and supermajority voting requirements.

Penumbra, Inc. has filed definitive additional materials related to its proxy statement with the Securities and Exchange Commission.

Penumbra, Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 5, 2024, to elect directors, ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm, and approve executive compensation on an advisory basis.

Vanguard Capital Management has reported beneficial ownership of 1,990,629 shares, representing 5.07% of Penumbra Inc.'s common stock, as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G for Penumbra Inc., reporting 0% beneficial ownership following an internal realignment and disaggregated reporting strategy.

FMR LLC and Abigail P. Johnson report a beneficial ownership of 4.7% in Penumbra Inc., marking a reduction below the 5% reporting threshold.

FMR LLC and Abigail P. Johnson have reported a 13.0% beneficial ownership stake in Penumbra Inc., holding over 5.1 million shares of common stock.

T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 3.3% in Penumbra Inc.'s common stock as of December 31, 2024.